LAVA Therapeutics N.V. Employee Directory
Biotechnology ResearchUtrecht, Netherlands2-10 Employees
LAVA Therapeutics N.V. is a clinical-stage biotechnology company based in Utrecht, in the Utrecht region, focused on cancer immunotherapy. It develops gamma-delta bispecific T-cell engagers designed to activate the Vγ9Vδ2 T-cell subset, mobilizing both innate and adaptive immune responses against tumor cells. The lead candidate, LAVA-051, targets CD1d, an antigen overexpressed in several blood cancers including multiple myeloma, CLL, and AML, with historical plans for a Phase I/IIa study in early 2021. The company aims to build a pipeline of therapies for both solid and hematologic malignancies. Recent news indicates that XOMA Corporation acquired LAVA Therapeutics in August 2025.